Gupta, S., Bedke, J., Heijden, M. S. V. D., Valderrama, B. P., Kikuchi, E., Hoffman-Censits, J., Iyer, G., Vulsteke, C., Rausch, S., Park, S. H., Drakaki, A., Arafat, W., Swami, U., Duran, I., Li, J., Moreno, B. H., Lichfield, J., Yu, X., Lu, Y., Powles, T. (2026). Characterization of patients (pts) responding to enfortumab vedotin plus pembrolizumab (EV+P): Exploratory analysis from the phase 3 EV-302 trial of EV+P vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.746